ABSTRACT
Objective:To explore the age-related changes of Pole2 expression levels in peripheral blood lymphocytes of healthy people, and analyze the differences of Pole2 expression levels in peripheral blood lymphocytes of four common senile disease patients between normal peers.Methods:Healthy people and patients in the physical examination center of Xuanwu Hospital of Capital Medical University from December 2018 to December 2019 were selected as the research objects, the mRNA and protein level of Pole2 in heathy individual as 20-29,30-39,40-49,50-59,60-69,70-79 y were checked by RT-PCR and Western blot,and the age-related curve was drew. The mRNA and protein expression levels of Pole2 were also detected in the peripheral blood lymphocytes of patients of DM,CHD,AD,CVD. And the deviation with healthy people of the same age was analyzed from one way ANOVA and repeated measurement were used to compare the mean of multiple groups.Results:The mRNA and protein levels of Pole2 increased in the lymphocytes of healthy people at 20-29 y and 50-59 y grouy, and decreased after 60-69 y and 70-79 y ( P<0.001). The Pole2 levels of mRNA and protein in the lymphocytes of patients of CHD,AD,DM and CVD cerebral atherosclerosis were significantly higher than that of healthy people of the same age. Moreover, the Pole2 level of lymphocytes of AD patients was significantly higher than that of other patient groups ( P<0.001). Conclusion:The expression level of Pole2 in peripheral blood lymphocytes increases with age before the age of 60 years old and decreases with age after 60 years old ;and the expression in four common senile diseases was higher than that in normal people.
ABSTRACT
Objective To systematically evaluate the effectiveness and safety of different calcium channel blockers (CCBs) in preventing stroke in hypertensive patients.Methods PubMed,Cochrane Library,Embase,Wanfang,CNKI,CBM,and other databases were comprehensively retrieved,and the randomized controlled trials of different CCBs in the prevention of stroke in hypertensive patients were collected.The retrieval time was from the establishment of the databases to November 5,2018.The languages were limited to Chinese and English.The literature screening,study inclusion,information extraction,and quality evaluation were independently conducted by two professional reviewers.A network diagram was drawn using Stata 13.0,and a meta-analysis of the included studies was performed using the Bayes model of the GeMTC 1.4.3 software.Results A total of 12 studies with 58 468 patients were enrolled.Network metaanalysis showed that nitrendipine (odds ratio 0.63,95％ confidence interval 0.44-0.89) and nifedipine (odds ratio 0.68,95％ confidence interval 0.46-0.92) were statistically significant in reducing the incidence of stroke.Other CCBs were not statistically significant in reducing the incidence of stroke,but had clinical differences.For the effectiveness of applying different CCBs to reduce the incidence of stroke,lacidipine should be preferred,followed by amlodipine,nitrendipine,nifedipine,and felodipine.However,there were no statistically significant differences in the effectiveness of different CCBs in preventing stroke.Conclusion Different CCBs can effectively reduce the incidence of stroke.In terms of specific drug types,lacidipine should be considered first,followed by amlodipine,nitrendipine,nifedipine,and felodipine.
ABSTRACT
Hepatocellular carcinoma (HCC) is a major health problem around the world and its morbidity is increasing year by year. HCC has a low rate of early diagnosis and advanced HCC has a low survival rate. Therefore, the diagnosis and treatment of HCC has attracted great attention, and tumor specific T cell immunity plays an important role in it. This article describes the immunological characteristics of seven HCC-associated antigen specific T cells, i.e., alpha fetal protein, phosphatidylinositol proteoglycan-3, NY-ESO-1, SSX-2, melanoma antigen gene A, telomerase reverse transcriptase, and HCC-associated antigen-519/target protein xklp-2, and analyzes the possible mechanisms which affect antigen specific T cell immunity from the aspects of regulatory T cells, myeloid-derived suppressor cells, antigen presenting and processing, inhibitory receptors, and CD4+T cells.
ABSTRACT
Objective To systematically review the efficacy and safety of nicergoline on chronic cerebrovascular insufficiency (CCVI).Methods Databases including the Cochrane Library,PubMed,CNKI,VIP and WanFang Date were electronically searched for relevant randomized controlled trails (RCTs) which studied the effectiveness and safety of Nicergoline on chronic cerebrovascular insufficiency.Two reviewers independently screened literature according to the inclusion and exclusion criteria,extracted data,and assessed the methodological quality.Metaanalysis was performed by using RevMan 5.2 software.Results Totally 9 studies involving 1 030 patients were included.The meta-analysis results showed that,compared with conventional treatment alone,the Nicergoline group was superior in improving the velocity of middle cerebral artery(MCA) in both systolic(MD=16.43,95％CI:10.39-22.46) and the late diastolic (MD=11.48,95％CI:5.34-17.63).Besides,Nicergoline significantly improved the pulse index (PI) of MCA (MD=-0.37,95％CI:-0.48--0.26).Likewise,it obviously improved the velocity in both systolic (MD=11.23,95％CI:6.10-16.35),the late diastolic (MD=8.80,95％CI:5.20-12.40) and the PI of vertebral artery (VA) (MD=-0.38,95％CI:-0.47--0.28).The remission rate of the nicergolinegroup was higher than that of the control group (OR=3.93,95％ CI:2.66-5.81).Drug-related adverse reactions were not reported in included studies.Conclusions Nicergoline shows a certain efficacy on CCVI without obvious adverse reactions.